Fluvoxamine-Clozapine Interaction — MRCPsych Paper B MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — Inhibition of CYP1A2-mediated hepatic metabolism of clozapine
Fluvoxamine is a strong CYP1A2 inhibitor. CYP1A2 is clinically important in clozapine metabolism, including its N-demethylation to norclozapine. Inhibition reduces clozapine clearance, increasing the parent-drug concentration and usually the clozapine-to-norclozapine ratio. The unchanged dose and absence of changes in smoking, caffeine intake or physical health support this interaction; sedation is consistent with the raised clozapine exposure. Only trace unchanged clozapine is renally excreted, so renal tubular competition is not responsible. CYP3A4 induction would tend to lower clozapine concentrations. Intestinal P-glycoprotein inhibition is not the established principal mechanism, while protein-binding displacement would not explain this sustained increase in total pre-dose concentration and altered metabolite ratio.
Reference: electronic Medicines Compendium, Faverin 50 mg Film-coated Tablets, Summary of Product Characteristics, section 4.5: Interaction with other medicinal products and other forms of interaction, updated 5 March 2026. https://www.medicines.org.uk/emc/product/1169/smpc